Search

Displaying results 2561 - 2570 of 10000 in total
  1. Drug

    renizgamglogene autogedtemcel

    go.drugbank.com/drugs/DB25530
    Investigational

    renizgamglogene autogedtemcel is a biologic drug. renizgamglogene autogedtemcel is under investigation in clinical trial NCT05444894 (EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in

    Synonyms: Autologous CD34+ hematopoietic stem and progenitor cells edited by CRISPR/CAS12a at the HBG1 and HBG2 promoters, autologous CD34+ hematopoietic stem and progenitor cells edited by CRISPR/Cas12a ribonucleoprotein (RNP) at the HBG1 and HBG2 promoters
  2. Drug

    Bethanechol

    go.drugbank.com/drugs/DB01019
    Approved

    system is necessary. … [A232905,L32539] As a cholinergic agent, bethanechol is similar in structure and pharmacological function to acetylcholine and is used in specific cases when stimulation of the parasympathetic nervous

  3. Drug

    Coenzyme M

    go.drugbank.com/drugs/DB09110
    ApprovedInvestigational

    Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.[A18572]

    Synonyms: HS-CoM
  4. Drug

    Agomelatine

    go.drugbank.com/drugs/DB06594
    ApprovedInvestigational

    In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011. … Agomelatine is structurally closely related to melatonin.

  5. Drug

    Cyclacillin

    go.drugbank.com/drugs/DB01000
    Approved

    A cyclohexylamido analog of penicillanic acid.

    Synonyms: (2S,5R,6R)-6-{[(1-aminocyclohexyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acidCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Teclistamab

    go.drugbank.com/drugs/DB16655
    ApprovedInvestigational

    Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells. … [A253587] On August 24, 2022, the European Commission (EC) granted conditional marketing authorization of teclistamab as first-in-class bispecific antibody for the treatment of multiple myeloma, marking

  7. Drug

    Peginterferon alfa-2b

    go.drugbank.com/drugs/DB00022
    ApprovedInvestigational

    Use of Peginterferon alfa-2b is associated with a wide range of severe adverse effects including the aggravation and development of endocrine and autoimmune disorders, retinopathies, cardiovascular and … The use of Peginterferon alfa-2b has largely declined since newer interferon-free antiviral therapies have been developed.

  8. Drug

    Gontivimab

    go.drugbank.com/drugs/DB16179
    Investigational

    Gontivimab is under investigation in clinical trial NCT03468829 (Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus

  9. Drug

    Measles virus vaccine live attenuated

    go.drugbank.com/drugs/DB10315
    ApprovedInvestigational

    Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. … The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture.

  10. Drug

    Panamesine

    go.drugbank.com/drugs/DB19466
    Experimental

    Panamesine is a small molecule drug. The usage of the INN stem '-mesine' in the name indicates that Panamesine is a sigma receptor ligand. Panamesine has a monoisotopic molecular weight of 426.18 Da.